pki-587 and trametinib

pki-587 has been researched along with trametinib* in 1 studies

Other Studies

1 other study(ies) available for pki-587 and trametinib

Article	Year
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 11-01, Volume: 28, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Kinase Kinases; Morpholines; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Triazines	2017

Article

Year

Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer.

Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 11-01, Volume: 28, Issue:11

Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Kinase Kinases; Morpholines; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Triazines

2017